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REPORT AND REVIEW OF LITERATURE
NEUROTOXICIDADE INDUZIDA PELA COLISTINA: RELATO DE CASO E 
REVISÃO DE LITERATURA
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ABSTRACT 
Objective: To describe a case of neurotoxity associated to Colistin. 
Case description: A 29-year-old black male under treatment for uri-
nary tract infection with identification of Klebsiella pneumoniae in 
urine culture resistant to all carbapenem antibiotics, presented visual 
turbidity, paresthesia on the face and upper left limb, slowed and dis-
cordant speech in the fourth day of Colistin use. Symptoms impro-
ved after reduction of the dose of colistin with adjustment for renal 
function, with complete reversion after discontinuation of the drug. 
Conclusions: Colistin-mediated neurotoxicity must be suspected in 
patients with altered mental status of unknown etiology and therapy 
promptly interrupted. 
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RESUMO
Objetivo: Descrever um caso de neurotoxidade associada à Colistina. 
Descrição do caso (desnecessário repetição): Um homem negro de 
29 anos sob tratamento para infecção do trato urinário com identifi-
cação de Klebsiella pneumoniae (escrever corretamente) em cultura 
de urina resistente a   carbapenêmicos, apresentou turvação visual, 
parestesia em face e membro superior esquerdo, discurso lento e 
discordante na quarto dia de uso da Colistina. Os sintomas melho-
raram após a redução da dose de colistina com ajuste para a função 
renal, com reversão completa após a descontinuação do fármaco. 
Conclusões:  A neurotoxicidade mediada por colistina deve ser sus-
peitada em pacientes com estado mental alterado de etiologia desco-
nhecida e a terapia prontamente interrompida.
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INTRODUCTION
Polymyxin class antibiotics are polypeptides dis-
covered in 1947 with potent Gram negative action and are 
used in clinical practice in the forms of polymyxin B and 
E, known as colistin. This drug class was widely used in 
the 1960s, but between the 1970s and 1980s its use was 
virtually abolished because of the side effects1.  Over the 
past 10 years, the advent of multi-resistant gram-negative 
microorganisms (MDR), such as Pseudomonas aerugino-
sa, Acinetobacter baumannii and Klebsiella pneumoniae, 
have brought back the use of polymyxins (polymyxin B 
and Colistin) as potential therapeutic agents2
Nephrotoxicity is the most common and well de-
scribed side effect of Colistin, characterized by the onset 
of renal injury, leading to acute renal failure and is consid-
ered as the major limitation of this class. Nevertheless, the 
occurrence of other toxicities related to colistin, such as 
neurological symptoms, have been described3,4.
Colistin-mediated neurotoxicity has been de-
scribed in the literature in fewer cases than renal injury 
and is characterized by various effects such as peripher-
al and facial paraesthesia, ophthalmoplegia, difficulty in 
swallowing, vertigo and respiratory apnea4,5possibly with 
low dose colistin. A 47-year-old hypertensive female with 
chronic kidney disease-5 with sepsis on colistimethate so-
dium 1 million units (80 mg.
Herein, we present a case of encephalopaty and 
peripherical neurological symptoms (as parestesias podem 
ser de natureza central, para serem de origem periférica 
o exame neurológico deveria mostrar alguma alteração 
como arreflexia profunda, hipoestesia com alteração típi-
ca de raiz ou nervo, ou melhor, ainda com distúrbio na 
eletroneuromiografia) related to the the administration of 
colistin. 
CASE REPORT
A 29-year-old black male with history of paraple-
gia, osteomyelitis of the right femur, chronic trochanteric 
decubitus ulcer, neurogenic bladder and recurrent urinary 
tract infection presented with purulent uninary discharge 
and fever. In urine culture, Klebsiella pneumoniae, identi-
fied by MALDI TOF (BioMérieux, Marcy l’Etoile, Fran-
ce), was isolated. The susceptibility test showed resistance 
to all carbapenem antibiotics, with meropenem MIC> 32 
ug / m Land sensibility to colistin, tigecyclin and amika-
cin. Blood cultures were negative. Renal function was nor-
mal at the beginning of t?. Renal function was normal at 
the onset of treatmente with intravenous colistin (5mg/kg 
loading dose, followed by 2,5mg/kg BID and amikacin 15/
mg/kg daily). 
On the second day of treatment, he presented nau-
sea and vomiting. Laboratory tests showed an increase of 
0.2 in creatinine levels, but still within the normal range. 
The next day, the patient presented mental confusion after 
infusion of the nocturnal dose, with spontaneous resolu-
tion. On the fourth day of treatment, he evolved with vi-
sual turbidity, paresthesia on the face and upper left limb, 
slowed and discordant speech. There were no changes in 
muscle strength, reflexes and cranial nerves. Skull CT was 
normal (Figure 1).(sendo normal não há necessidade de 
mostrar a foto: ocupa espaço e nada acrescenta ao traba-
lho) New laboratory tests showed increased Creatinine 
(3,4 mg/dl) and potassium (6,0 mmol/L) levels. Due to re-
nal disfunction, amikacin was replaced for double carbap-
enem therapy (Ertapenem 1g/daily, followed by Meropen-
em 2g QID) and Tigeciclin (100mg loading dose followed 
by 50mg BID). Symptoms improved after reduction of the 
dose of colistin with adjustment for renal function, with 
complete reversion after discontinuation of the drug.
LITERATURE REVIEW
METHODS
Data for this review were obtained through lite-
rature searches of publications included in PubMed from 
2006 to 2017 and references cited in relevant articles. The 
main search terms used in searches were ‘polymixin’, 
‘colistin’, adverse effects’, ‘neurotoxicity’ and ‘toxicity’. 
Also, secondary search was performed through the refe-
rences of the articles found. Only English language papers 
were reviewed. 
RESULTS
Table 1 summarizes the available publications re-
porting data regarding the incidence of colistin mediated 
neutoxicity.
Neurotoxicity is a side effect of colistin much less 
described than nephrotoxicity and is resolved upon discon-
tinuation of therapy. The incidence of neurotoxicity (most 
paresthesia) reported with the use of polymyxin has been 
reported to be approximately 7% in recent studies6. Intra-
thecal administration is related to a higher incidence with 
a incidence of 20% of meningeal irritation and seizures3. 
In the other cases, the most frequente experienced neuro-
Colistin Neurotoxity
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logical adverse events were paraesthesias that occurred 
in approximately 27% and 7.3% of patients receiving in-
travenous and intramuscular colistimethate, respectively3. 
Less common symptoms included diplopia, ptosis, nystag-
mus, hallucinations, ataxia, seizures and partial deafness7.
Similar to nephrotoxicity, the risk of neurotoxicity 
is associated with increased exposure to the drug, such as 
longer duration of therapy or increased dose. Other risk 
factors for neurotoxicity include hypoxia and use of con-
comitant medications such as sedatives, anesthetics, mus-
cle relaxants, narcotics or corticosteroids6. Also, patients 
with renal insufficiency or myasthenia gravis are at increa-
sed risk of developing neuromuscular block and respira-
tory paralysis3. 
Few studies have evaluated the the mechanism of 
colistin-induced neurotoxicity. Behavioral changes, mus-
cle weakness and ataxia were observed in mice and rats 
exposed to Colistin8. Axonal degeneration and demyeli-
zation were also reported when mice were intravenously 
administered with 15 mg / kg / day colistin for 7 days9. 
Colistin-induced electrophysiological changes in vivo are 
not well elucidated.
In the case reported herein as well as in the re-
viewed cases, all patients had a full recovery of neurologic 
symtoms after discontinuation of colistin and additional 
therapies. 
DISCUSSION
The emergence of multidrug resistant gram-nega-
tive bacteria in the recent decade has led to the revival of 
polymyxin antibiotics and has also brought concern to its 
adverse effects10. Colistin associated neurotoxity, although 
still a rare effect, has been described in some case reports. 
The neurological findings are variable. Some individuals 
present mild to moderate symptoms11,12, as our patient, in-
volving visual turbidity, paresthesia and slowed speech. 
Nevertheless, severe cases of neurotoxity have been re-
ported, incluiding respiratory muscle paralysis1,2
The proposed mechanism of colistin associated 
neurotoxity is a noncompetitive myoneuronal presynaptic 
blockade of acetylcholine release that may be enhanced 
by hypocalcemia-induced prolongation of depolariza-
tion13”ISBN” : “1460-2091 (Electronic. Risk factors for 
developing neurological side effects include abnormal re-
nal function and concomitant drug therapies including oth-
er neurotoxic drugs such as anesthetics, aminoglycosides, 
corticosteroids, and muscle relaxants14. 
Herein, we reported a case of neurotoxity in a pa-
tient without previous impairment of the central nervous 
system. Altough he presented normal renal function at the 
onset of treatment, he was doing concomitant use of ami-
kacin, which may have contributted to worsening renal 
function and colistin neurological side effects. Neurolog-
ical diseases such as stroke were excluded in this patient. 
He was not receiving any steroids or muscle relaxants.
Studies that clarify the optimal dosing of colistin 
are unclear. Thus, regular monitoring of renal function as 
well as monitoring the neurological status is important to 
prevent and manage the toxicities associated with colistin 
use. In all cases, should drug be discontinued and there is 
no reversal agents14.  As this reaction can be reversible, 
continuous renal replacement therapy or hemodialysis may 
be a reasonable option to help in patients with acute renal 
failure or with high serum levels of polymyxins1. Progno-
sis of adverse colistin toxicity is generally good and once 
the agent is discontinued recovery may take up to 72 h4.
Also, it is important to point that in our review, 
data from the recent studies suggest that the frequence of 
of toxicity resulting from the use of polymyxins is lower 
and less severe wheen compared to what has been previ-
ously described in 60s-70s10,14. This discrepance may be 
due the avoidance of co- administration of nephrotoxic 
and/or neurotoxic drugs, careful dosing, as well as more 
meticulous management of fluid and electrolyte abnormal-
ities and use of critical care practices1,14. 
In conclusion, although less frequent than previ-
ouly desbribed, the diagnosis of plumixin-mediated neu-
rotoxicity should be suspeccted in patients with altered 
mental status of unknown aetiology. Prompt interruption 
of therapy is indicated to avoid any fatal consequences.
Lírio M, et al.
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Figure 1: Skull tomography performed to rule out stroke.
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